Deepak Sundriyal ¹ *, Neeraj Jain ² , Mukesh Mamgain ¹ , Bhawana Adhikari ¹ , Indrani Sarkar ¹ and Uttam Kumar Nath ¹

¹Department of Medical Oncology Hematology, All India Institute of Medical Sciences, Rishikesh, India
²Department of Cancer Biology, Central Drug Research Institute, Lucknow, India

*Corresponding Author: Deepak Sundriyal, Department of Medical Oncology Hematology, All India Institute of Medical Sciences, Rishikesh, India.

Received: February 04, 2026; Published: March 04, 2026

Abstract

Multiple myeloma (MM) is a biologically heterogeneous plasma cell malignancy characterized by clonal proliferation within the bone marrow and progressive end-organ damage. Despite advances in therapy, MM remains largely incurable, with relapse and drug resistance representing major clinical challenges. Genomic and transcriptomic studies have improved understanding of MM biology; however, these approaches do not fully capture functional disease mechanisms, which are ultimately governed at the protein level. Proteomics offers a dynamic and functionally relevant platform to explore disease heterogeneity, tumor–microenvironment interactions, and mechanisms of therapeutic resistance. This study proposes comprehensive proteomic profiling of malignant plasma cells from treatment-naïve MM patients to characterize intrinsic disease biology prior to therapy-induced alterations. Conducted at All India Institute of Medical Sciences (AIIMS), Rishikesh in collaboration with Central Drug Research Institute (CDRI), Lucknow, the study includes newly diagnosed MM patients and healthy controls. Bone marrow samples undergo cryopreservation, CD138⁺ plasma cell isolation using magnetic- activated cell sorting, and flow cytometric confirmation, followed by high-resolution proteomic analysis. Correlation of proteomic signatures with clinicopathological parameters, treatment response, and survival outcomes is planned. Validation of key deregulated proteins will be performed using reverse-transcriptase polymerase chain reaction based transcriptomic analysis. The study is particularly relevant in the Indian context, where MM often presents at a younger age, with more frequent extramedullary disease and suboptimal therapeutic response. By identifying dysregulated signalling pathways, novel biomarkers, and potential therapeutic targets, this research aims to improve risk stratification and contribute to personalized treatment strategies. Overall, the work seeks to bridge existing gaps in Indian MM proteomics and advance translational myeloma research.

Keywords: Multiple Myeloma; Proteomics; Plasma Cells; Signalling Pathways; Disease Biology

References

1. Kyle RA and Rajkumar SV. “Multiple myeloma”. Blood 6 (2008): 2962-2972.
2. Hanbali A., et al. “The evolution of prognostic factors in multiple myeloma”. Advances in Hematology (2017): 4812637.
3. Palumbo A and Anderson K. “Multiple myeloma”. The New England Journal of Medicine 11 (2011): 1046-60.
4. Hu S., et al. “Post-Translational Modifications in Multiple Myeloma: Mechanisms of Drug Resistance and Therapeutic Opportunities”. Biomolecules 15.5 (2025): 702.
5. Fotiou D and Katodritou E. “From Biology to Clinical Practice: The Bone Marrow Microenvironment in Multiple Myeloma”. Journal of Clinical Medicine2 (2025): 327.
6. Di Marzo L., et al. “Microenvironment drug resistance in multiple myeloma: emerging new players”. Oncotarget 37 (2016): 60698-711.
7. Payne SH. “The utility of protein and mRNA correlation”. Trends in Biochemical Science 1 (2015): 1-3.
8. Johnson SK., et al. “The use of molecular-based risk stratification and pharmacogenomics for outcome prediction and personalized therapeutic management of multiple myeloma”. International Journal of Hematology4 (2011): 321-333.
9. Cheung CHY and Juan HF. “Quantitative proteomics in lung cancer”. Journal of Biomed Science 24 (2017): 37.
10. Rees-Unwin KS., et al. “Proteomics and the haematologist”. Clinical Laboratory Hematology 4 (2004): 77-86.
11. Ge F., et al. “Proteomics: addressing the challenges of multiple myeloma”. Acta Biochimica et Biophysica Sinica (Shanghai) 2 (2011): 89-95.
12. Mitsiades CS., et al. “Proteomic analysis in Waldenstrom’s macroglobulinemia and other plasma cell dyscrasias”. Seminar on Oncology 2 (2003): 156-160.
13. Yin L. “Chondroitin synthase 1 is a key molecule in myeloma-osteoclast interactions”. Journal of Biological Chemistry 16 (2005): 15666-15672.
14. Rees-Unwin KS., et al. “Proteomics and the haematologist”. Clinical Laboratory Hematology 2 (2004): 77-86.
15. Ge F., et al. “Proteomic and functional analyses reveal a dual molecular mechanism underlyimg arsenic-induced apoptosis in human myeloma cells”. Journal of Proteome Research 8 (2009): 3006-3019.
16. Paradeisi F., et al. “Proteomic Analysis of Bone Marrow CD138+ Cells to Identify Proteins Associated With the Response of Multiple Myeloma Patients to Commonly Used Therapeutic Regimens”. Proteomics16 (2025): 48-60.
17. Wu X., et al. “Serum proteome profiling identified thrombospondin-1 and lactoferrin as biomarkers of relapsed multiple myeloma”. Frontiers in Medicine (Lausanne) 12 (2025): 1640245. 
18. Landgren O and Weiss BM. “Patterns of monoclonal gammopathy of undetermined significance and multiple myeloma in various ethnic/racial groups: support for genetic factors in pathogenesis”. Leukemia 10 (2008): 1691-1697.
19. Rollig C., et al. “Multiple Myeloma”. Lancet 385 (2015): 2197-2208.
20. “Global cancer observatory”. Globocan (2022).
21. Bhutani M., et al. “Lympho-hemopoietic malignancies in India”. Medical Oncology3 (2002): 141-150.
22. Gupta P., et al. “A twelve year study of multiple myeloma at the All India Institute of Medical Sciences, New Delhi, India”. Indian Journal of Medical and Paediatric Oncology 16 (1995): 108-114.
23. Usha Agarwal N., et al. “Myeloma in young age”. Indian Journal of Pathology and Microbiology3 (2005): 314-317.
24. Dhiman P., et al. “FISH analysis in multiple myeloma - a retrospective study from India”. Blood 128 (2016): 5646.
25. Kadam Amare PS., et al. “Observation on frequency & clinic-pathological significance if various cytogenetic in multiple myeloma: an experience from India”. The Indian Journal of Medical Research 144 (2016): 536-543.
26. Chanukuppa V., et al. “XPO1 is a critical player for bortezomib resistance in multiple myeloma: A quantitative proteomic approach”. Journal of Proteomics 209 (2019): 103504. 
27. Chanukuppa V., et al. “Proteomic Alterations in Multiple Myeloma: A Comprehensive Study Using Bone Marrow Interstitial Fluid and Serum Samples”. Frontiers in Oncology 10 (2021): 566804.
28. Chanukuppa V., et al. “Proteomics and functional study reveal marginal zone B and B1 cell specific protein as a candidate marker of multiple myeloma”. International Journal of Oncology 1 (2020): 325-337. 

Citation

Citation: Deepak Sundriyal., et al. “Designing a Proteomic Study Protocol in Multiple Myeloma: Methodological Framework, Technical Workflow, Data Analysis and Translational Considerations". Acta Scientific Cancer Biology 10.1 (2026): 35-48.

Copyright

Copyright: © 2026 Deepak Sundriyal., et al.This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.